Lee Spain
Psychiatry · Meadville, PANPI 1427281559
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 63.1% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $12,243 and has fallen 70.2% since, to $3,648 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 977 payments — averaging $43.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$27K
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Johnson & Johnson$1K
- AbbVie$974
- plus $7K from 27 others
What the payments were for
- Consulting fees$3,8009%
- Speaking & faculty fees$19,57046%
- Travel & lodging$8292%
- Food & beverage$17,41341%
- Education$6141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 111 | $26,652 |
| Teva Pharmaceuticals USA, Inc. | 207 | $3,197 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 60 | $1,991 |
| Otsuka America Pharmaceutical, Inc. | 66 | $1,559 |
| Johnson & Johnson | 46 | $1,011 |
| AbbVie(2 entities) | 64 | $974 |
| Neurocrine Biosciences, Inc. | 57 | $960 |
| Lundbeck LLC | 60 | $888 |
| Takeda Pharmaceuticals U.S.A., Inc. | 76 | $784 |
| Merck | 32 | $526 |
| Axsome Therapeutics, Inc. | 29 | $502 |
| Vanda Pharmaceuticals Inc. | 24 | $494 |
| Corium, LLC | 21 | $418 |
| Ironshore Pharmaceuticals Inc. | 12 | $354 |
| E.r. Squibb & Sons, L.L.C. | 19 | $315 |
| Eisai Inc. | 17 | $228 |
| Sunovion Pharmaceuticals Inc. | 18 | $217 |
| Sage Therapeutics, LLC | 9 | $198 |
| Avanir Pharmaceuticals, Inc. | 8 | $186 |
| Indivior Inc. | 9 | $146 |
| Supernus Pharmaceuticals, Inc. | 6 | $117 |
| Novo Nordisk | 6 | $102 |
| Jazz Pharmaceuticals Inc. | 3 | $100 |
| Shire North American Group Inc | 4 | $66 |
| Tris Pharma Inc | 3 | $51 |
| Collegium Pharmaceutical, Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Boston Scientific | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $23 |
| Neos Therapeutics, LP | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Neuronetics, Inc. | 1 | $18 |
| Bioxcel Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$99,323
- ARISTADA INITIO$24,831
- CAPLYTA$708
- REXULTI$484
- LYBALVI$480
- AUSTEDO$359
- Jornay PM 20mg capsules (Bottle of 100)$139
- VRAYLAR$125
- ABILIFY MAINTENA$125
- INVEGA SUSTENNA$112
- INVEGA TRINZA$112
- Azstarys$111
How this compares
$42,226 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 117 | $331,519 |
| IngrezzaValbenazine Tosylate | 35 | $294,187 |
| HetliozTasimelteon | 13 | $263,523 |
| Austedo XrDeutetrabenazine | 12 | $96,352 |
| RexultiBrexpiprazole | 54 | $81,274 |
| TrintellixVortioxetine Hydrobromide | 99 | $66,221 |
| Abilify MaintenaAripiprazole | 21 | $61,075 |
| AristadaAripiprazole Lauroxil | 13 | $41,022 |
| VraylarCariprazine Hcl | 23 | $29,645 |
| FetzimaLevomilnacipran Hcl | 52 | $28,537 |
| BelsomraSuvorexant | 44 | $20,091 |
| CaplytaLumateperone Tosylate | 11 | $17,418 |
| Aripiprazole | 389 | $15,901 |
| Paliperidone ErPaliperidone | 91 | $13,902 |
| QuviviqDaridorexant Hcl | 25 | $12,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,011 | $331,519117 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $960 | $294,18735 claims |
| Vanda Pharmaceuticals Inc.Hetlioz | $494 | $263,52313 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,559 | $142,34975 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $3,197 | $96,35212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $784 | $77,342130 claims |
| AbbVieVraylar, Fetzima | $974 | $58,18275 claims |
| Alkermes, Inc.Aristada | $26,652 | $41,02213 claims |
| MerckBelsomra | $526 | $20,09144 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,991 | $17,41811 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $30 | $12,88325 claims |
| Eisai Inc.Dayvigo | $228 | $9,75929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Meadville
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.